Publications

 


  • 604. Correlation between stage shift and differences in mortality in the European Randomized study of Screening for Prostate Cancer (ERSPC).

    Bokhorst LP, Zappa M, Carlsson SV, Kwiatkowski M, Denis L, Paez A, Hugosson J, Moss S, Auvinen A, Roobol MJ, 2016

    Journal: BJU Int
    Reference: Apr 22.

  • 603. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.

    Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J, 2016

    Journal: Eur Urol
    Reference: Apr 15

  • 602. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

    Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H, 2016

    Journal: Eur Urol
    Reference: Apr 12.

  • 601. Number of screening rounds and post-screening prostate cancer incidence: Results from the Finnish section of ERSPC study.

    Pakarainen T, Raitanen J, Talala K, Taari K, Kujala P, Tammela TLJ, Auvinen A, 2016

    Journal: Eur Urol
    Reference: In press

  • 600. Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

    Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J, 2016

    Journal: Clin Cancer Res
    Reference: In press

  • 599. Prostate cancer and socioeconomic status in the Finnish Randomized Study of Screening for Prostate Cancer.

    Kilpeläinen T, Talala K, Raitanen J, Tammela TLJ, Kujala P, Taari K, Auvinen A, 2016

    Journal: Am J Epidemiol 2016
    Reference: In press

  • 598. Family history in the Finnish Prostate Cancer Screening Trial.

    Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A, 2015

    Journal: Int J Cancer
    Reference: 136(9):2172-7

  • 597. Postscreening follow-up of the Finnish Prostate Cancer Screening Trial on putative prostate cancer risk factors: vitamin and mineral use, male pattern baldness, pubertal development and non-steroidal anti-inflammatory drug use.

    Sarre S, Määttänen L, Tammela TL, Auvinen A, Murtola TJ, 2016

    Journal: Scan J Urol
    Reference: 29:1-7

  • 596. Non-steroidal anti-inflammatory drugs and cancer death in the Finnish Prostate Cancer Screening Trial.

    Veitonmäki T, Murtola TJ, Tammela TL, Talala K, Taari K, Auvinen A, 2016

    Journal: PLoS One
    Reference: 11(4):e0153413

  • 595. Sotalol, but not digoxin is associated with decreased prostate cancer risk. A population-based case-control study.

    Kaapu KJ, Ahti J, Tammela TLJ, Auvinen A, Murtola TJ, 2015

    Journal: Int J Cancer
    Reference: 137(5):1187-95

  • 594. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.

    Kaapu KJ, Murtola TJ, Määttänen L, Talala K, Taari K, Tammela TL, Auvinen A, 2016

    Journal: Cancer Causes Control
    Reference: 27(2):157-64.

  • 593. The Finnish prostate cancer screening trial: analyses on the screening failures.

    Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A, 2015

    Journal: Int J Cancer
    Reference: 136(10):2437-43

  • 592. 5-alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

    Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A, 2016

    Journal: Int J Cancer
    Reference: 138(12):2820-8

  • 591. Polymorphisms of Genes Involved in Glucose and Energy Metabolic Pathways and Prostate Cancer: Interplay with Metformin.

    Murtola TJ, Wahlfors T, Haring A, Taari K, Stenman UH, Tammela TL; PRACTICAL Consortium, Schleutker J, Auvinen A, 2015

    Journal: Eur Urol
    Reference: 68(6):1089-97

  • 590. The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer

    Godtman RA, Carlsson S, Holmberg E, Stranne J, Hugosson J, 2015

    Journal: J Urol
    Reference: Dec 8.

  • 589. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Goteborg Randomised Screening Trial

    Grenabo Bergdahl A, Wilderäng U, Aus G, Carlsson S, Damber J-E, Frånlund M, Geterud K, Khatami A, Socratous A, Stranne J, Hellström M, Hugosson J, 2015

    Journal: Eur Urol
    Reference: Dec 24.

  • 588. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).

    Randazzo M, Müller A, Carlsson S, Eberli D, Huber A, Grobholz R, Manka L, Mortezavi A, Sulser T, Recker F, Kwiatkowski M., 2015

    Journal: BJU Int.
    Reference: Aug 31.

  • 587. Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.

    Pashayan N, Pharoah PD, Schleutker J, Talala K, Tammela TLj, Määttänen L, Harrington P, Tyrer J, Eeles R, Duffy SW, Auvinen A, 2015

    Journal: Br J Cancer
    Reference: Sep 29;113(7):1086-93

  • 586. Differences among men on active surveillance for very low-risk prostate cancer detected through population-based versus opportunistic prostate-specific antigen-screening.

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Recker F, Kwiatkowski M, 2015

    Journal: Urol Int.
    Reference: 94(3):330-6.

  • 585. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the finnish prostate cancer screening trial.

    Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL, Auvinen A, 2015

    Journal: Prostate
    Reference: Jun 12.

  • 584. Prostate cancer screening using risk stratification based on a multi-state model of genetic variants.

    Yen AM, Auvinen A, Schleutker J, Wu YY, Fann JC, Tammela T, Chen SL, Chiu SY, Chen HH, 2015

    Journal: Prostate
    Reference: Jun;75(8):825-35.

  • 583. Ethnicity and prostate cancer: the way to solve the screening problem?

    Bokhorst LP, Roobol MJ, 2015

    Journal: BMC Med.
    Reference: Aug 4;13:179

  • 582. Early detection of prostate cancer–recommendations after 13 years of follow-up in the European randomised study

    Schröder FH, Roobol MJ, Bangma CH, 2015

    Journal: Ned Tijdschr Geneeskd.
    Reference: 159:A8677.

  • 581. Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.

    Venderbos LD1, Roobol MJ, Bangma CH, van den Bergh RC, Bokhorst LP, Nieboer D, Godtman R, Hugosson J, van der Kwast T, Steyerberg EW, 2015

    Journal: World J Urol.
    Reference: Jul 10.

  • 580. Prostate cancer screening in Europe – Authors’ reply.

    Schröder F, Hugosson J, Carlsson S, Moss S, Roobol M, Auvinen A, 2015

    Journal: Lancet
    Reference: Apr 18;385(9977):1507-8

  • 579. Corrigendum to “Incidence of Prostate Cancer After Termination of Screening in a Population-based Randomised Screening Trial” [Eur Urol 2013;64:703-9].

    Bergdahl AG, Holmberg E, Moss S, Hugosson J, 2015

    Journal: Eur Urol
    Reference: Aug;68(2):e46.

  • 578. Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

    Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M, 2015

    Journal: Eur Urol.
    Reference: Mars 16

  • 577. Is further screening of men with baseline PSA < 1ng/ml worthwhile? the discussion continues - results of the Swiss ERSPC (Aarau).

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Kluth LA, Wyler SF, Recker F, Kwiatkowski M, 2015

    Journal: Int J Cancer
    Reference: Aug 1;137(3):553-9.

  • 576. Prostate cancer screening: and yet it moves!

    Kwiatkowski M, Randazzo M, Kluth L, Manka L, Huber A, Recker F, 2015

    Journal: Asian J Androl
    Reference: May-Jun;17(3):437-8.

  • 575. The Finnish prostate cancer screening trial: Analyses on the screening failures.

    Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L, Stenman UH, Kujala P, Auvinen A, 2015

    Journal: Int J Cancer
    Reference: May 15;136(10):2437-43.

  • 574. Opportunistic Testing Versus Organized Prostate-specific Antigen Screening: Outcome After 18 Years in the Göteborg Randomized Population-based Prostate Cancer Screening Trial.

    Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J., 2014

    Journal: Eur Urol
    Reference: Dec 31.

  • 573. Reply from Authors re: Sigrid V. Carlsson, Peter C. Albertsen. Better Survival After Curative Treatment for Screen-detected Prostate Cancer Compared with Clinical Diagnosis: A Real Effect or Lead-time Bias? Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.10.035: Better Treatment in the Control Arm of the ERSPC Rotterdam: A Point Worth Noting?

    Bokhorst LP, Roobol MJ, Kranse R, 2014

    Journal: Eur Urol
    Reference: Nov 20.

  • 572. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

    Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ, 2014

    Journal: Eur Urol
    Reference: Dec;66(6):1109-15.

  • 571. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

    Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ, 2014

    Journal: J Natl Cancer Inst
    Reference: Dec 13;107(1):366.

  • 570. Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam.

    Bokhorst LP, Kranse R, Venderbos LD, Salman JW, van Leenders GJ, Schröder FH, Bangma CH, Roobol MJ; for the ERSPC Rotterdam Study Group, 2015

    Journal: Eur Urol
    Reference: Aug;68(2):179-82.

  • 569. Influence of metformin use on PSA values, free‑to‑total PSA, prostate cancer incidence and grade and overall survival in a prospective screening trial (ERSPC Aarau)

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Wyler SF, Chun FF, Recker F, Kwiatkowski M, 2014

    Journal: World J Urol
    Reference: Oct 31

  • 568. Family history in the finnish prostate cancer screening trial.

    Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, Auvinen A, 2015

    Journal: Int J Cancer.
    Reference: May 1;136(9):2172-7.

  • 567. Prostate cancer: Rescreening policies and risk calculators.

    Roobol MJ, 2014

    Journal: Nat Rev Urol.
    Reference: Aug;11(8):429-30.

  • 566. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

    Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; for the ERSPC Investigators, 2014

    Journal: Lancet.
    Reference: Aug 6.

  • 565. Screening for prostate cancer: current status of ERSPC and screening-related issues.

    Schröder FH., 2014

    Journal: Recent Results Cancer Res.
    Reference: 202:47-51.

  • 564. Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores >=100.

    Schröder FH, Venderbos LD, van den Bergh RC, Hessels D, van Leenders GJ, van Leeuwen PJ, Wolters T, Barentsz JO, Roobol MJ., 2014

    Journal: Urology
    Reference: Mar;83(3):613-6.

  • 563. International perspectives on screening.

    Roobol MJ., 2014

    Journal: Urol Clin North Am
    Reference: May;41(2):237-47.

  • 562. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence.

    Wilt TJ, Scardino PT, Carlsson SV, Basch E., 2014

    Journal: J Natl Cancer Inst.
    Reference: Mar;106(3):dju010.

  • 561. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

    Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A., 2014

    Journal: BMJ
    Reference: Mar 28;348:g2296.

  • 560. A “PSA Pyramid” for Men with Initial Prostate-specific Antigen ≤3 ng/ml: A Plea for Individualized Prostate Cancer Screening.

    Randazzo M, Beatrice J, Huber A, Grobholz R, Manka L, Chun FK, Recker F, Kwiatkowski M., 2014

    Journal: Eur Urol
    Reference: 14-04-18

  • 559. Overdiagnosis and Overtreatment of Prostate Cancer.

    Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R, 2014

    Journal: Eur Urol
    Reference: Jan 9. pii: S0302-2838(13)01490-5.

  • 558. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

    Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H, 2014

    Journal: BMC Med
    Reference: Feb 11;12:26.

  • 557. RE: Prostate-Specific Antigen Screening Trials and Prostate Cancer Deaths: The Androgen Deprivation Connection.

    Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A, 2014

    Journal: J Natl Cancer Inst
    Reference: Apr 26;106(5).

  • 556. Overdetection in screening for prostate cancer.

    Hugosson J, Carlsson S, 2014

    Journal: Curr Opin Urol
    Reference: May;24(3):256-63.

  • 555. Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening For Prostate Cancer (ERSPC).

    Luján M, Páez A, Angulo JC, Granados R, Nevado M, Torres GM, Berenguer A., 2014

    Journal: Prostate Cancer Prostatic Dis
    Reference: Jun;17(2):187-91.

Next →